Pacira BioSciences/$PCRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Ticker

$PCRX
Primary listing

Industry

Pharmaceuticals

Employees

789

ISIN

US6951271005

PCRX Metrics

BasicAdvanced
$1.1B
-
-$2.27
0.56
-

What the Analysts think about PCRX

Analyst ratings (Buy, Hold, Sell) for Pacira BioSciences stock.

Bulls say / Bears say

Pacira BioSciences announced a $300 million share repurchase program, signaling confidence in its financial health and commitment to enhancing shareholder value. (nasdaq.com)
The company reported better-than-expected preliminary Q4 2024 sales figures, with Exparel's net product sales reaching $147.7 million, a 3% increase from the previous year. (nasdaq.com)
Pacira unveiled promising three-year clinical data for its investigational gene therapy, PCRX-201, showing sustained improvements in knee osteoarthritis patients, which could lead to future product approvals and revenue streams. (stocktitan.net)
In Q3 2024, Pacira reported a $163.2 million impairment charge, significantly impacting its financial results and raising concerns about asset valuation. (stocktitan.net)
The company faced a legal setback when a U.S. court deemed its '495 patent for Exparel invalid, potentially opening the market to generic competition and affecting future revenues. (zacks.com)
Insider trading activity over the past six months shows that company executives have sold shares, which might indicate a lack of confidence in the stock's short-term performance. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

PCRX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PCRX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PCRX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs